Plasma multianalyte profiling in mild cognitive impairment and alzheimer disease

Neurology

Volumn 80, Issue 7, 2013, Pages 690-691

  Bennett, David A ^a   Hu, William T ^a   Holtzman, David ^a   Shaw, Leslie ^a   Trojanowski, John ^a   Soares, Holly ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 3; PROTEOME;

ALZHEIMER DISEASE; BLOOD ANALYSIS; HUMAN; HUMAN GENOME; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC DISEASE; NOTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; BLOOD; FEMALE; MALE;

ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT;

EID: 84875850355     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000427396.91304.3d     Document Type: Note

References (10)

1. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multi-analyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012;79:897-905.
2. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus Report of the Working Group on molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging 1998;19:109-116.
3. Vidal M, Chan DW, Gerstein M, et al; Workshop Participants. The human proteome: a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clin Proteomics 2012;9:6.
4. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200-208.
5. Arnold SE, Louneva N, Cao K, et al. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol Aging 2013;34:157-168.
6. Iwamoto N, Nishiyama E, Ohwada J, et al. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 1994;117:23-26.
7. Silverman JM, Schmeidler J, Beeri MS, et al. C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging. Neurology 2012;79:1116-1123.
8. Hu WT, Chen-Plotkin A, Arnold SE, et al. novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010;119:669-678.
9. Craig-Schapiro R, Kihn M, Xiong C, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011;6:e18850.
10. Schonberger SJ, Edgar PF, Kydd R, et al. Proteomic analysis of the brain in Alzheimer's disease: molecular pheno-type of a complex disease process. Proteomics 2001;1: 1519-1528.